메뉴 건너뛰기




Volumn , Issue , 2008, Pages 144-158

High-Throughput Screening and Drug Discovery

Author keywords

[No Author keywords available]

Indexed keywords


EID: 77956299850     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00007-X     Document Type: Chapter
Times cited : (4)

References (91)
  • 1
    • 6444234760 scopus 로고    scopus 로고
    • The role of medicinal chemistry in drug discovery - then and now
    • Lombardino J.G., Lowe J.A. The role of medicinal chemistry in drug discovery - then and now. Nat. Rev. Drug Discov. 2004, 3:853-862.
    • (2004) Nat. Rev. Drug Discov. , vol.3 , pp. 853-862
    • Lombardino, J.G.1    Lowe, J.A.2
  • 2
    • 0034677966 scopus 로고    scopus 로고
    • Drug discovery: a historical perspective
    • Drews J. Drug discovery: a historical perspective. Science 2000, 287:1960-1963.
    • (2000) Science , vol.287 , pp. 1960-1963
    • Drews, J.1
  • 3
    • 84882483876 scopus 로고    scopus 로고
    • For example, during the first four years of the discovery campaign that led to cimetidine, some 200 compounds were synthesized and assessed. Ganellin, C. R. Discovery of the antiulcer drug tagamet. In Drug Discovery and Development (Chorghade, M. S., Ed.), John Wiley & Sons, Inc, Hoboken, New Jersey
    • For example, during the first four years of the discovery campaign that led to cimetidine, some 200 compounds were synthesized and assessed. Ganellin, C. R. Discovery of the antiulcer drug tagamet. In Drug Discovery and Development (Chorghade, M. S., Ed.), John Wiley & Sons, Inc, Hoboken, New Jersey, Vol. 1, p. 300.
    • , vol.1 , pp. 300
  • 4
    • 10844263277 scopus 로고
    • Pharmacological screening tests
    • Smith W.G. Pharmacological screening tests. Progr. Med. Chem. 1964, 1:1-33.
    • (1964) Progr. Med. Chem. , vol.1 , pp. 1-33
    • Smith, W.G.1
  • 5
    • 0023713884 scopus 로고
    • Drug discovery - today and tomorrow: the role of medicinal chemistry
    • Freter K.R. Drug discovery - today and tomorrow: the role of medicinal chemistry. Pharmaceut. Res. 1988, 5:397-400.
    • (1988) Pharmaceut. Res. , vol.5 , pp. 397-400
    • Freter, K.R.1
  • 7
    • 33646517064 scopus 로고    scopus 로고
    • Drug discovery: selecting the optimal approach
    • Sams-Dodd F. Drug discovery: selecting the optimal approach. Drug Discov. Today 2006, 11:465-472.
    • (2006) Drug Discov. Today , vol.11 , pp. 465-472
    • Sams-Dodd, F.1
  • 8
    • 0024146165 scopus 로고
    • Cyclosporins, fungal metabolites with immunosuppressive activities
    • Von Wartburg A., Traber R. Cyclosporins, fungal metabolites with immunosuppressive activities. Progr. Med. Chem. 1988, 25:1-33.
    • (1988) Progr. Med. Chem. , vol.25 , pp. 1-33
    • Von Wartburg, A.1    Traber, R.2
  • 9
    • 0024959451 scopus 로고
    • Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin
    • Takahashi N., Hayano T., Suzuki M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989, 337:473-475.
    • (1989) Nature , vol.337 , pp. 473-475
    • Takahashi, N.1    Hayano, T.2    Suzuki, M.3
  • 12
    • 0038270983 scopus 로고
    • Hydroxyurea, a new type of potential antitumor agent
    • Stearns B., Losee K.A., Bernstein J. Hydroxyurea, a new type of potential antitumor agent. J. Med. Chem. 1963, 6:201.
    • (1963) J. Med. Chem. , vol.6 , pp. 201
    • Stearns, B.1    Losee, K.A.2    Bernstein, J.3
  • 13
    • 73649185176 scopus 로고
    • Experimental evaluation of potential anticancer agents. VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia
    • Schabel F.M., Johnston T.P., McCaleb G.S., Montgomery J.A., Laster W.R., Skipper H.E. Experimental evaluation of potential anticancer agents. VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. Cancer Res. 1963, 23:725-733.
    • (1963) Cancer Res. , vol.23 , pp. 725-733
    • Schabel, F.M.1    Johnston, T.P.2    McCaleb, G.S.3    Montgomery, J.A.4    Laster, W.R.5    Skipper, H.E.6
  • 15
    • 0014596980 scopus 로고
    • Chemotherapy and comparative biochemistry: G. H. A. Clowes memorial lecture
    • Hitchings G.H. Chemotherapy and comparative biochemistry: G. H. A. Clowes memorial lecture. Cancer Res. 1969, 29:1895-1903.
    • (1969) Cancer Res. , vol.29 , pp. 1895-1903
    • Hitchings, G.H.1
  • 16
    • 0031024171 scopus 로고    scopus 로고
    • Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    • Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23:3-25.
    • (1997) Adv. Drug Deliv. Rev. , vol.23 , pp. 3-25
    • Lipinski, C.A.1    Lombardo, F.2    Dominy, B.W.3    Feeney, P.J.4
  • 17
    • 0034461768 scopus 로고    scopus 로고
    • Drug-like properties and the causes of poor solubility and poor permeability
    • Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Meth. 2001, 44:235-249.
    • (2001) J. Pharmacol. Toxicol. Meth. , vol.44 , pp. 235-249
    • Lipinski, C.A.1
  • 18
    • 0037468884 scopus 로고    scopus 로고
    • A comparison of physiochemical property profiles of development and marketed oral drugs
    • Wenlock M.C., Austin R.P., Barton P., Davis A.M., Leeson P.D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46:1250-1256.
    • (2003) J. Med. Chem. , vol.46 , pp. 1250-1256
    • Wenlock, M.C.1    Austin, R.P.2    Barton, P.3    Davis, A.M.4    Leeson, P.D.5
  • 20
    • 0035324944 scopus 로고    scopus 로고
    • Molecular complexity and the impact on finding leads for drug discovery
    • Hann M.M., Leach A.R., Harper G. Molecular complexity and the impact on finding leads for drug discovery. J. Chem. Inform. Comput. Sci. 2001, 41:856-864.
    • (2001) J. Chem. Inform. Comput. Sci. , vol.41 , pp. 856-864
    • Hann, M.M.1    Leach, A.R.2    Harper, G.3
  • 21
    • 0036589285 scopus 로고    scopus 로고
    • Current trends in lead discovery: Are we looking for the appropriate properties?
    • Oprea T. Current trends in lead discovery: Are we looking for the appropriate properties?. J. Comput.-Aided Mol. Des. 2002, 16:325-334.
    • (2002) J. Comput.-Aided Mol. Des. , vol.16 , pp. 325-334
    • Oprea, T.1
  • 23
    • 12844283957 scopus 로고    scopus 로고
    • High-throughput drug discovery: What can we expect from HTS?
    • Gribbon P., Sewing A. High-throughput drug discovery: What can we expect from HTS?. Drug Discov. Today 2005, 10:17-22.
    • (2005) Drug Discov. Today , vol.10 , pp. 17-22
    • Gribbon, P.1    Sewing, A.2
  • 24
    • 0038387389 scopus 로고    scopus 로고
    • A guide to drug discovery: Hit and lead generation: beyond high-throughput screening
    • Bleicher K.H., Böhm H.J., Müller K., Alanine A.I. A guide to drug discovery: Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov 2003, 2:369-378.
    • (2003) Nat. Rev. Drug Discov , vol.2 , pp. 369-378
    • Bleicher, K.H.1    Böhm, H.J.2    Müller, K.3    Alanine, A.I.4
  • 26
    • 0034093179 scopus 로고    scopus 로고
    • Quantized surface complementarity diversity (QSCD): a model based small molecule-target complementarity
    • Wintner E.A., Moallemi C.C. Quantized surface complementarity diversity (QSCD): a model based small molecule-target complementarity. J. Med. Chem. 2000, 43:1993-2006.
    • (2000) J. Med. Chem. , vol.43 , pp. 1993-2006
    • Wintner, E.A.1    Moallemi, C.C.2
  • 29
    • 84882526755 scopus 로고    scopus 로고
    • Compound collections: acquisition, annotation and access
    • The Royal Society of Chemistry, Cambridge, P.A. Bartlett, M. Entzeroth (Eds.)
    • Richardson R. Compound collections: acquisition, annotation and access. Exploiting Chemical Diversity for Drug Discovery 2006, 113-136. The Royal Society of Chemistry, Cambridge. P.A. Bartlett, M. Entzeroth (Eds.).
    • (2006) Exploiting Chemical Diversity for Drug Discovery , pp. 113-136
    • Richardson, R.1
  • 30
    • 0345511077 scopus 로고    scopus 로고
    • Supplement
    • Anon Nature 1996, 384:1-5. Supplement.
    • (1996) Nature , vol.384 , pp. 1-5
    • Anon1
  • 31
    • 0033003760 scopus 로고    scopus 로고
    • A simple statistical parameter for use in evaluation and validation of high throughput screening assays
    • Zhang J-H., Chung T.D.Y., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 1999, 4:67-73.
    • (1999) J. Biomol. Screen , vol.4 , pp. 67-73
    • Zhang, J.-H.1    Chung, T.D.Y.2    Oldenburg, K.R.3
  • 32
    • 0037439447 scopus 로고    scopus 로고
    • Nonleadlikeness and leadlikeness in biochemical screening
    • Rishton G.M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today 2002, 8:86-96.
    • (2002) Drug Discov. Today , vol.8 , pp. 86-96
    • Rishton, G.M.1
  • 35
    • 33745188660 scopus 로고    scopus 로고
    • Screening in a spirit haunted world
    • Soichet B.K. Screening in a spirit haunted world. Drug Discov. Today 2006, 11:607-615.
    • (2006) Drug Discov. Today , vol.11 , pp. 607-615
    • Soichet, B.K.1
  • 36
    • 0037061628 scopus 로고    scopus 로고
    • A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening
    • McGovern S.L., Caselli E., Grigorieff N., Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45:1712-1722.
    • (2002) J. Med. Chem. , vol.45 , pp. 1712-1722
    • McGovern, S.L.1    Caselli, E.2    Grigorieff, N.3    Shoichet, B.K.4
  • 38
    • 33645887230 scopus 로고    scopus 로고
    • Critical review of the role of HTS in drug discovery
    • Macarron R. Critical review of the role of HTS in drug discovery. Drug Discov. Today 2006, 11:277-279.
    • (2006) Drug Discov. Today , vol.11 , pp. 277-279
    • Macarron, R.1
  • 39
    • 33746294770 scopus 로고    scopus 로고
    • The hit-to-lead process at Schering AG: strategic aspects
    • Steinmeyer A. The hit-to-lead process at Schering AG: strategic aspects. ChemMedChem 2006, 1:31-36.
    • (2006) ChemMedChem , vol.1 , pp. 31-36
    • Steinmeyer, A.1
  • 45
    • 84882479009 scopus 로고    scopus 로고
    • Preparation of pharmaceutically active heterocyclic amines and their use for treating head injury, spinal trauma, stroke, etc. WO8808424 (1988 Upjohn Co.)
    • McCall, J. M., Ayer, D. E., Jacobsen, E. J., Van Doornik, F. J., Palmer, J. R. Preparation of pharmaceutically active heterocyclic amines and their use for treating head injury, spinal trauma, stroke, etc. WO8808424 (1988 Upjohn Co.).
    • McCall, J.M.1    Ayer, D.E.2    Jacobsen, E.J.3    Van Doornik, F.J.4    Palmer, J.R.5
  • 51
    • 0031006108 scopus 로고    scopus 로고
    • 2-Aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists
    • 2-Aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists. J. Med. Chem. 1997, 40:1682-1689.
    • (1997) J. Med. Chem. , vol.40 , pp. 1682-1689
    • Wu, C.1    Chan, M.F.2    Stavros, F.3    Raju, B.4    Okun, I.5    Castillo, R.S.6
  • 61
  • 64
    • 33745298429 scopus 로고    scopus 로고
    • Rational design of inhibitors that bind to inactive kinase conformations
    • Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2:358-364.
    • (2006) Nat. Chem. Biol. , vol.2 , pp. 358-364
    • Liu, Y.1    Gray, N.S.2
  • 67
    • 84882483890 scopus 로고    scopus 로고
    • Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2 WO2001058890 (Astrazeneca)
    • Baxter, A., Brough, S., Faull, A., Johnstone, C., Mcinally, T. Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2 WO2001058890 (Astrazeneca).
    • Baxter, A.1    Brough, S.2    Faull, A.3    Johnstone, C.4    Mcinally, T.5
  • 68
    • 84882517370 scopus 로고    scopus 로고
    • Preparation of aminothiophenes as NF-KB inhibitors. WO2003029242 (2003 Smithkline Beecham Corporation, USA). Parrish, C.A., Callahan, J.F., Wan, Z., Burgess, J. L., Stavenger, R. A., Holt, D. A. Preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders. WO2003028731 (Smithkline Beecham Corporation)
    • Wan, Z., Burgess, J. L., Callahan, J. F. Preparation of aminothiophenes as NF-KB inhibitors. WO2003029242 (2003 Smithkline Beecham Corporation, USA). Parrish, C.A., Callahan, J.F., Wan, Z., Burgess, J. L., Stavenger, R. A., Holt, D. A. Preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders. WO2003028731 (Smithkline Beecham Corporation).
    • Wan, Z.1    Burgess, J.L.2    Callahan, J.F.3
  • 70
    • 84882527719 scopus 로고    scopus 로고
    • Heteroaromatic carboxamide derivatives, particularly 3-aminothiophene-2-carboxamides, useful as protein kinase inhibitors, for the treatment of cancer, inflammation, and inflammation-related disorders. WO2003037886 (Pharmacia Corporation, USA)
    • Graneto, M., Hanau, C. E., Perry, T. D. Heteroaromatic carboxamide derivatives, particularly 3-aminothiophene-2-carboxamides, useful as protein kinase inhibitors, for the treatment of cancer, inflammation, and inflammation-related disorders. WO2003037886 (Pharmacia Corporation, USA).
    • Graneto, M.1    Hanau, C.E.2    Perry, T.D.3
  • 71
    • 84882498246 scopus 로고    scopus 로고
    • Preparation of substituted thiophene carboxamide compounds for the treatment of inflammation. (Pharmacia Corporation, USA). WO2004009582
    • Hagen, T. J., Weier, R. M., Xu, X., Houdek, S. C., Clare, M. Preparation of substituted thiophene carboxamide compounds for the treatment of inflammation. (Pharmacia Corporation, USA). WO2004009582.
    • Hagen, T.J.1    Weier, R.M.2    Xu, X.3    Houdek, S.C.4    Clare, M.5
  • 72
    • 0037124196 scopus 로고    scopus 로고
    • Drugs, leads, and drug-likeness: an analysis of some recently launched drugs
    • Proudfoot J.R. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 2002, 12:1647-1650.
    • (2002) Bioorg. Med. Chem. Lett. , vol.12 , pp. 1647-1650
    • Proudfoot, J.R.1
  • 73
    • 33748742351 scopus 로고    scopus 로고
    • High content screening moves to the front of the line
    • Haney S.A., LaPan P., Pan J., Zhang J. High content screening moves to the front of the line. Drug Discov. Today. 2006, 11:889-894.
    • (2006) Drug Discov. Today. , vol.11 , pp. 889-894
    • Haney, S.A.1    LaPan, P.2    Pan, J.3    Zhang, J.4
  • 74
    • 32444441360 scopus 로고    scopus 로고
    • Computational chemistry driven decision making in lead generation
    • Schnecke V., Bostrom J. Computational chemistry driven decision making in lead generation. Drug Discov. Today. 2006, 11:43.
    • (2006) Drug Discov. Today. , vol.11 , pp. 43
    • Schnecke, V.1    Bostrom, J.2
  • 79
    • 0028106163 scopus 로고
    • Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor
    • Ward W.H.J., Cook P.N., Slater A.M., Davies D.H., Holdgate G.A., Green L.R. Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48:659-666.
    • (1994) Biochem. Pharmacol. , vol.48 , pp. 659-666
    • Ward, W.H.J.1    Cook, P.N.2    Slater, A.M.3    Davies, D.H.4    Holdgate, G.A.5    Green, L.R.6
  • 86
    • 0033956395 scopus 로고    scopus 로고
    • Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-carbonyl)benzanilid e derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzazepine-6-carbonyl)benzanilide derivative
    • Matsuhisa A., Taniguchi N., Koshio H., Yatsu T., Tanaka A. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-carbonyl)benzanilid e derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzazepine-6-carbonyl)benzanilide derivative. Chem. Pharmaceut. Bull. 2000, 48:21-31.
    • (2000) Chem. Pharmaceut. Bull. , vol.48 , pp. 21-31
    • Matsuhisa, A.1    Taniguchi, N.2    Koshio, H.3    Yatsu, T.4    Tanaka, A.5
  • 88
    • 0032474915 scopus 로고    scopus 로고
    • Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
    • Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., Tang C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem. 1998, 41:2588-2603.
    • (1998) J. Med. Chem. , vol.41 , pp. 2588-2603
    • Sun, L.1    Tran, N.2    Tang, F.3    App, H.4    Hirth, P.5    McMahon, G.6    Tang, C.7
  • 91
    • 27744548649 scopus 로고    scopus 로고
    • The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS
    • Wood A., Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Progr. Med. Chem. 2005, 43:239-271.
    • (2005) Progr. Med. Chem. , vol.43 , pp. 239-271
    • Wood, A.1    Armour, D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.